Indications
Therapeutic Asset Ratings
5,098 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Lenvatinib
Endometrial Cancer
Merck Sharp & Dohme LLC
P3
B
(61)
Lenvatinib
Neoplasm
Tongji Hospital
P3
B
(61)
Leuporelin
Castration-Resistant Prostate Carcinoma
Bayer
P3
B
(61)
ly01005
Prostate Cancer
The First Affiliated Hospital of Xiamen University
P3
B
(61)
Maralixibat
Cholestasis
Mirum Pharmaceuticals, Inc.
P3
B
(61)
Methotrexate
Acute Biphenotypic Leukemia
Fred Hutchinson Cancer Center
P3
B
(61)
Methotrexate
B-Cell Adult Acute Lymphocytic Leukemia
Massachusetts General Hospital
P3
B
(61)
Methotrexate
B-Cell Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
P3
B
(61)
Methotrexate
Childhood Myelodysplastic Syndrome
Children's Oncology Group
P3
B
(61)
Msdc-0602K
Metabolic Dysfunction-Associated Steatohepatitis
Cirius Therapeutics, Inc.
P3
B
(61)
Multiple Vitamins Injection
Skin Carcinoma
Women's College Hospital
P3
B
(61)
N-Butyl Cyanoacrylate
Periampullary Adenocarcinoma
Minia University
P3
B
(61)
Neratinib
Breast Cancer
Xijing Hospital
P3
B
(61)
Nivestim
Hodgkins Lymphoma
Thomas Jefferson University
P3
B
(61)
Nivestim
Follicular Lymphoma
Fred Hutchinson Cancer Center
P3
B
(61)
Ntla-2002
Hereditary Angioedema
Intellia Therapeutics
P3
B
(61)
Olaparib
Fallopian Tube Cancer
University of Colorado, Denver
P3
B
(61)
Osimertinib
Neoplasm
Innovent Biologics (Suzhou) Co. Ltd.
P3
B
(61)
Pcbhp
Breast Cancer
Fudan University
P3
B
(61)
Pelabresib
Cancer
Novartis Pharmaceuticals
P3
B
(61)
Ponesimod
Multiple Sclerosis
Biogen
P3
B
(61)
Ppsv23
Relapsing-Remitting Multiple Sclerosis
Celgene
P3
B
(61)
Pyrotinib
Colorectal Cancer
Anbogen Therapeutics, Inc.
P3
B
(61)
Recombinant Human Hyaluronidase
Non-Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P3
B
(61)
Rel-1017
Major Depressive Disorder
MGGM LLC
P3
B
(61)
Showing 2576 to 2600 of 5,098 assets
Previous
Page 104 of 204
Next